Skip to content
STOKStoke Therapeutics, Inc.

Earnings

When Stoke Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

35 quarters. Mar 31, 2018 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Jan 11, after the close

Mon, Jan 11, 2027in 55 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 8 – 26

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$1.40M
Revenue, change from a year earlier: Q3 2026 +5.9%, Q2 2026 −32.5%, Q1 2026 −96.1%, Q4 2025 −93.8%
Net income
-$57.93M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$11.26M+5.9% vs Q3 2025

Latest results

  1. Q3 2026Oct 29, 2026, after the closeThe release0.3%by the close of Oct 30
    Revenue
    $11.26M
    +5.9%
    Net income
    -$73.64M
    N/M
    EPS
    -$1.08
    N/M
    On October 29, 2026, Stoke Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter end September 30, 2026.
  2. Q2 2026Aug 3, 2026, after the closeThe release+7.0%by the close of Aug 4
    Revenue
    $9.33M
    −32.5%
    Net income
    -$61.62M
    N/M
    EPS
    -$0.93
    N/M
  3. Q1 2026May 7, 2026, after the closeThe release+0.4%by the close of May 8
    Revenue
    $6.23M
    −96.1%
    Net income
    -$50.00M
    N/M
    EPS
    -$0.79
    N/M
  4. Q4 2025Jan 12, 2026, before the openThe release10.4%by the close of Jan 12
    Revenue
    $1.40M
    −93.8%
    Net income
    -$57.93M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Oct 29, 2026 · after-hoursNov 3, 202634 d10-Q$11.26M+5.9%-$1.080.3%
Q2 2026Jun 30, 2026Aug 3, 2026 · after-hoursAug 3, 202634 d10-Q$9.33M−32.5%-$0.93+7.0%
Q1 2026Mar 31, 2026May 7, 2026 · after-hoursMay 7, 202637 d10-Q$6.23M−96.1%-$0.79+0.4%
FY 2025
Q4 2025derivedDec 31, 2025Jan 12, 2026 · pre-marketMar 16, 202675 d10-K$1.40M−93.8%—10.4%
Q3 2025Sep 30, 2025Nov 4, 2025 · after-hoursNov 4, 202535 d10-Q$10.63M+117.2%-$0.6510.0%
Q2 2025Jun 30, 2025Aug 12, 2025 · after-hoursAug 12, 202543 d10-Q$13.82M+186.0%-$0.40+25.0%
Q1 2025Mar 31, 2025May 13, 2025 · pre-marketMay 13, 202543 d10-Q$158.57M+3,661.1%$1.907.6%
FY 2024
Q4 2024derivedDec 31, 2024Mar 18, 2025 · pre-marketMar 18, 202577 d10-K$22.61M+707.4%—1.6%
Q3 2024Sep 30, 2024Nov 5, 2024 · pre-marketNov 5, 202436 d10-Q$4.89M+47.9%-$0.470.2%
Q2 2024Jun 30, 2024Aug 7, 2024 · pre-marketAug 7, 202438 d10-Q$4.83MN/M-$0.46—
Q1 2024Mar 31, 2024May 6, 2024 · pre-marketMay 6, 202436 d10-Q$4.22M−18.2%-$0.57—
Earlier years, FY 2018 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 3, 2026445326
10-QAug 3, 2026330557
10-QMay 7, 2026211874
10-KMar 16, 2026108362
10-QNov 4, 2025264720
10-QAug 12, 2025107332
10-QMay 13, 2025070296
10-KMar 18, 2025041170
10-QNov 5, 2024121445
10-QAug 7, 2024092738

Provenance

ProvenanceData status and checks

Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR